Stem Cell Sheet Using Self-Secreted ECM for Tissue Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for tissue repair, such as surgical reattachment and tissue engineering, face challenges including slow healing, limited success rates, and risks of tissue rejection, donor site morbidity, and the need for appropriate cell types and scaffold materials that support effective regeneration without causing inflammatory responses or tumor formation.
Innovation Solution
A cell sheet composed of treated stem cells embedded in their self-secreted extracellular matrix, incorporating biological factors like TGF-β, CTGF, and ascorbic acid, and potentially genetic modifications, to promote tissue-specific differentiation and regeneration, which can be used alone or with other cell types and growth factors for tissue repair and bio-artificial tissue engineering.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional surgical reattachment or conservative treatments are used for tissue repair, then the treatment can be performed with existing methods, but the healing process is slow and often results in fibrotic scarring with diminished mechanical strength
Solution Approach 1:
The patent applies preliminary action by pre-differentiating stem cells into tissue-specific cells (tenocytes, chondrocytes, osteoblasts) before transplantation. This preliminary differentiation ensures that the transplanted cells are already committed to the desired tissue lineage, accelerating the healing process and preventing fibrotic scarring by establishing proper tissue architecture from the outset rather than relying on slow spontaneous differentiation during the healing process.
Solution Approach 2:
The patent employs self-service through the use of self-secreted extracellular matrix (ECM) produced by the stem cells themselves. The cells generate their own native ECM scaffold, which provides a biocompatible framework for tissue regeneration without requiring external synthetic scaffolds. This self-assembled ECM promotes organized tissue formation and maintains mechanical strength while eliminating the need for implantation of foreign materials.
2Adaptability or versatility
If mesenchymal stem cells are used for tissue engineering, then the cells have self-renewal potential and can differentiate into multiple lineages, but there is a risk of erroneous differentiation and tumor formation
Solution Approach 1:
The patent applies preliminary action by pre-differentiating stem cells into specific tissue lineages (tenocytes for tendon, chondrocytes for cartilage, osteoblasts for bone) using lineage-specific growth factors and biochemical cues before transplantation. This preliminary commitment to a specific differentiation pathway reduces the risk of erroneous differentiation and tumor formation by ensuring cells are already committed to a safe, functional lineage before being implanted into the patient.
Solution Approach 2:
The patent employs feedback mechanisms through the use of lineage-specific growth factors (such as TGF-β for tenocyte differentiation, BMPs for osteoblast differentiation) that provide biochemical signals to guide stem cell differentiation. These growth factors create a feedback loop where the differentiation state of the cells is continuously regulated by the presence of appropriate signaling molecules, ensuring proper lineage commitment and reducing the risk of uncontrolled proliferation or erroneous differentiation.
3Reliability
If autografts or allografts are used for tissue replacement, then the repair can be performed surgically, but there are risks of donor site morbidity, disease transmission, and tissue rejection
Solution Approach 1:
The patent employs self-service by using the patient's own stem cells (autologous stem cells) that are harvested, expanded, and differentiated in vitro, then returned to the patient for transplantation. This self-service approach eliminates the risks associated with allografts (disease transmission, rejection) because the cells are genetically identical to the patient. It also avoids donor site morbidity because the stem cells are obtained from the patient's own body without requiring a separate donor site harvest procedure.
Solution Approach 2:
The patent uses an intermediary approach by culturing and differentiating stem cells in a controlled in vitro environment using specific growth factors and biochemical cues. This intermediary step between harvesting and transplantation allows for cell expansion, lineage commitment, and quality control, ensuring that the cells are optimized for the specific tissue repair needed while eliminating the direct risks of surgical grafting procedures.
4Strength
If synthetic scaffolds are used for tissue engineering, then the structural support can be provided, but the biocompatibility is poor and inflammatory responses occur
Solution Approach 1:
The patent employs self-service by utilizing the self-secreted extracellular matrix (ECM) produced by the stem cells themselves as the scaffold. The cells generate native ECM components (collagen, proteoglycans, glycoproteins) that form a biocompatible, three-dimensional framework supporting tissue regeneration. This self-assembled ECM provides the necessary structural support while being fully biocompatible and eliminating inflammatory responses associated with synthetic scaffolds.
Solution Approach 2:
The patent uses composite materials through the combination of stem cells and their self-secreted extracellular matrix to create a living, functional tissue construct. The ECM provides the structural scaffold while the embedded stem cells provide biological activity, creating a composite system that combines the mechanical support of a scaffold with the regenerative capabilities of living cells, resulting in a biocompatible tissue engineering solution.
Data Source
AI summary
Disclosed is a cell sheet for tissue repair and bio-artificial tissue engineering. The cell sheet comprises treated stem cell embedded in its self-secreted extracellular matrix (ECM) and formed a cell sheet. The cell sheet is formed by isolating the stem cell, expanding the stem cell and treating the stem cell with biological factors or factors leading to the production of biological factors, to induce its differentiation, production of extracellular matrix and formation of a cell sheet in vitro. The cell sheet is used as a bioactive material or as an acellular material for the promotion of tissue repairs or used to form a bio-artificial organ for tissue replacement. The cell sheet of the present invention eliminates the need to use scaffolds for cell delivery. The cell sheet facilitates in vivo cell transplantation and provides some tensile mechanical strength for bearing early mechanical load during tissue repair.